TrialCompass TCL
Back to results
Phase 1RecruitingPriority 4 · Lower priorityNCT07164560

Exploratory Study of Umbilical Cord Blood-Derived CAR-NK Cell Therapy Targeting TRBC1/2 for Relapsed/Refractory T-Cell Lymphoma

ClinicalTrials.gov

Plain-language summary

This Phase 1 trial is testing Anti-TRBC1 CAR-T cells for people whose T-cell lymphoma has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. This trial does not currently list US sites.

Who can join (key eligibility)

  • Age 18 Years to 75 Years years
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Anti-TRBC1 CAR-T cells (BIOLOGICAL): Umbilical cord blood-derived NK cells transduced with lentiviral vector express anti-TRBC1 CAR

Drugs / treatments
Anti-TRBC1 CAR-T cells
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

Exploratory Study of Umbilical Cord Blood-Derived CAR-NK Cell Therapy Targeting TRBC1/2 for Relapsed/Refractory T-Cell Lymphoma

NCT07164560

Phase: Phase 1 | Status: Recruiting | Priority: Lower

Plain-language summary

This Phase 1 trial is testing Anti-TRBC1 CAR-T cells for people whose T-cell lymphoma has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. This trial does not currently list US sites.

Who can join

  • Age 18 Years to 75 Years years
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)

What's being tested

Anti-TRBC1 CAR-T cells (BIOLOGICAL): Umbilical cord blood-derived NK cells transduced with lentiviral vector express anti-TRBC1 CAR

Drugs / treatments: Anti-TRBC1 CAR-T cells

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 45 patients

Primary endpoint: Incidence of dose limiting toxicity (DLTs)

Ages: 18 Years to 75 Years

Start date: 2026-04-01 | Est. completion: 2029-04-01

Locations

0 US sites · 1 total

Contact

Wenbin Qian, professor | Qianwb@zju.edu.cn | 87-57189713672

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University (OTHER)

Tags

All T-cell lymphomas · Relapsed/Refractory

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT07164560

Prepared using TrialCompass (trialcompass.com) on June 19, 2026. For informational purposes only. Always discuss with your healthcare team.